003020 Hefei Lifeon Pharmaceutical
- 19.40
- -0.26-1.32%
Hefei Lifeon Pharmaceutical News
Cube Pharmaceuticals (003020.SZ): Onsite inspection of methylphenidate hydrochloride extended-release tablets was completed in April 2024, and approval results are expected in 2025
Gelonghui May 24 | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The situation of methylphenidate hydrochloride extended-release tablets?” The company replied that methylphenidate hydrochloride sustained-release tablets are three-layer osmosis pump sustained-release tablets. The application was accepted in the fourth quarter of last year, on-site inspection was completed in April 2024, and approval results are expected in 2025.
Cube Pharmaceuticals (003020.SZ): Ketone Tongluo capsules are currently mainly sold in medical institutions, and there are few retail channels
On May 24, Ge Longhui | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The status of ketone access capsules?” The company replied that currently it is mainly sold in medical institutions, and there are few retail channels, and there is still a lot of room for improvement in hospital coverage.
Cube Pharmaceuticals (003020.SZ): Sales volume of nifedipine controlled-release tablets increased significantly after collection in countries that won the bid
Gelonghui May 24 | Cube Pharmaceuticals (003020.SZ) was surveyed by investors on May 23, 2024, on “the status of controlled release nifedipine tablets?” The company replied that the sales volume of nifedipine controlled-release tablets increased significantly after collection in the country that won the bid, and fixed costs were better shared.
Cube Pharmaceuticals (003020.SZ): Opioid analgesics have more room for future growth
Gelonghui May 24 | Cube Pharmaceutical (003020.SZ) was surveyed by investors on May 23, 2024, on “The situation of oxycodone hydrochloride sustained-release tablets?” The company replied that there is a lot of room for future growth in opioid analgesics. Among them, oxycodone hydrochloride is used in a relatively high proportion of oral medications for cancer pain. After the company launched oxycodone hydrochloride sustained-release tablets in 2023, it was mainly development and admission work, focusing on the development of key hospitals.
Further Upside For Hefei Lifeon Pharmaceutical Co., Ltd. (SZSE:003020) Shares Could Introduce Price Risks After 25% Bounce
Hefei Lifeon Pharmaceutical Co., Ltd. (SZSE:003020) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Unfortunately, the gains of the last month did little to
Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution
Hefei Lifeon Pharmaceutical's (SHE:003020) unit, Hefei Chengzhi Biopharmaceutical, received the drug registration for the loxoprofen sodium oral solution from China's National Medical Products Adminis
Cube Pharmaceuticals (003020.SZ): 2023 equity distribution of 10 to 2 transfers of 5 yuan equity registration date May 27
On May 20, Ge Longhui Pharmaceutical (003020.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 5.000000 in cash (including tax) to all shareholders for every 10 shares based on the company's total share capital excluding 159,643,136 shares after 0 shares have been repurchased, and at the same time, transfer 2.000000 shares to all shareholders for every 10 shares. The share registration date for this equity distribution is May 27, 2024, and the ex-dividend date is May 28, 2024.
Cube Pharmaceuticals (003020.SZ): Loxoprofen Sodium Oral Solution Drug Registration and Marketing License Application Accepted
On May 20, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Chengzhi Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of Hefei Cube Pharmaceutical Co., Ltd., received a “Notice of Acceptance” of the application for registration and marketing of loxoprofen sodium oral solution drugs issued by the State Drug Administration. Loxoprofen sodium is a phenylpropionic acid nonsteroidal anti-inflammatory drug. It has good analgesic, anti-inflammatory and antipyretic effects, especially strong analgesic effects. Indications are: ① anti-inflammatory and analgesic pain for rheumatoid arthritis, osteoarthritis, lower back pain, shoulder joint inflammation, neck, shoulder and wrist syndrome, toothache; ② trauma after surgery
Cube Pharmaceuticals (003020.SZ) reported first-quarter results, net profit of 30.3722 million yuan, a year-on-year decrease of 54.08%
Cube Pharmaceuticals (003020.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Market Cap Increased by CN¥496m, Insiders Receive a 60% Cut
Key Insights Hefei Lifeon Pharmaceutical's significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 54% of the company Institutions own 15% of H
Cube Pharmaceuticals (003020.SZ) announced its 2023 annual results, with net profit of 227 million yuan, an increase of 8.33%
Cube Pharmaceutical (003020.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 1...
Cube Pharmaceuticals (003020.SZ): Mesalazine enteric tablet drug registration and marketing license application accepted
On February 26, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. received a “Notice of Acceptance” for the registration and marketing license application for mesalazine enteric tablets issued by the State Drug Administration. Mesalazine is a non-steroidal anti-inflammatory drug that can inhibit the synthesis of prostaglandins that cause inflammation and the formation of inflammatory mediators leukotriene, thereby significantly inhibiting inflammation of the intestinal mucosa. The product applying for marketing approval is mesalazine enteric tablets, which release mesalazine in the intestines after oral administration. They are suitable for the treatment of acute episodes of ulcerative colitis and maintenance to prevent recurrence
Cube Pharmaceuticals (003020.SZ): Application for marketing registration of tampiol raw materials accepted
Cube Pharmaceutical (003020.SZ) issued an announcement. Recently, the company received Danpi issued by the State Drug Administration...
Cube Pharmaceuticals (003020.SZ): Application for marketing registration of propmecaine hydrochloride as an API was accepted
On February 19, Gelonghui Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. (received the “Notice of Acceptance” of the application for marketing registration of propmecaine hydrochloride raw materials issued by the State Drug Administration. Promethacaine hydrochloride is a potent ester surface anesthetic. Its preparation, propmecaine hydrochloride eye drops, is clinically mainly used for surface ophthalmic anesthesia, etc., and is a fast-acting local anesthetic. As of the announcement date, there are no imported API registrations for promecaine hydrochloride APIs. In addition to the company, there are currently five domestic API companies registered and filed. Three of them have a registration status of “A
Investors Don't See Light At End Of Hefei Lifeon Pharmaceutical Co., Ltd.'s (SZSE:003020) Tunnel And Push Stock Down 27%
The Hefei Lifeon Pharmaceutical Co., Ltd. (SZSE:003020) share price has fared very poorly over the last month, falling by a substantial 27%. The drop over the last 30 days has capped off a tough ye
Cube Pharmaceuticals (003020.SZ) once again passed the high-tech enterprise certification
Gelonghui, January 19, Cube Pharmaceutical (003020.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Anhui Provincial Department of Science and Technology, the Anhui Provincial Department of Finance, and the Anhui Provincial Taxation Bureau of the State Administration of Taxation.
Cube Pharmaceuticals (003020.SZ): Application for marketing of the novel antipsychotic drug “paliperidone sustained-release tablets” accepted
Cube Pharmaceutical (003020.SZ) announced that recently, the company received paliperidone issued by the State Drug Administration...
Lifeon Pharma's Diabetes Drugs Pass China Consistency Evaluation
Hefei Lifeon Pharmaceutical (SHE:003020) said two of its drugs for diabetes have passed the National Medical Products Administration's consistency evaluation. Lifeon's Metformin and Glipizide tablets
Cube Pharmaceuticals (003020.SZ): Metformin glipizide tablets passed a consistent evaluation of the quality and efficacy of generic drugs
Gelonghui on December 20丨Cube Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company” or “Cube Pharmaceutical”) received the “Notice of Approval of Drug Supplement Applications” for metformin glipizide tablets approved and issued by the State Drug Administration (Notice No.: 2023B06435). The company's metformin glipizide tablets passed a consistent evaluation of the quality and efficacy of generic drugs. Metformin glipizide tablets are a combination of metformin and glipizide. They are suitable for type II diabetics who cannot fully and effectively control blood sugar with diet or exercise therapy.
Cube Pharmaceuticals (003020.SZ): Doxazosin mesylate extended-release tablets passed a consistent evaluation of the quality and efficacy of generic drugs
Glonghui December 19丨Cube Pharmaceutical (003020.SZ) announced that recently, Hefei Cube Pharmaceutical Co., Ltd. received the “Notice of Approval of Supplemental Drug Application” for doxazosin mesylate extended-release tablets issued by the State Drug Administration (Notice No.: 2023B06360). The company's doxazosin mesylate extended-release tablets passed a consistent evaluation of the quality and efficacy of generic drugs. The indications for doxazosin mesylate extended-release tablets are symptomatic treatment of benign prostatic hyperplasia; hypertension.
Analysis
Price Target
No Data
